Literature DB >> 24203988

Pancreatic cancer death rates by race among US men and women, 1970-2009.

Jiemin Ma1, Rebecca Siegel, Ahmedin Jemal.   

Abstract

BACKGROUND: Few studies have examined trends in pancreatic cancer death rates in the United States, and there have been no studies examining recent trends using age-period-cohort analysis.
METHODS: Annual percentage change in pancreatic cancer death rates was calculated for 1970 to 2009 by sex and race among adults aged 35 to 84 years using US mortality data provided by the National Center for Health Statistics and Joinpoint Regression. Age-period-cohort modeling was performed to evaluate the changes in cohort and period effects. All statistical tests were two-sided.
RESULTS: In white men, pancreatic cancer death rates decreased by 0.7% per year from 1970 to 1995 and then increased by 0.4% per year through 2009. Among white women, rates increased slightly from 1970 to 1984, stabilized until the late 1990s, then increased by 0.5% per year through 2009. In contrast, the rates among blacks increased between 1970 and the late 1980s (women) or early 1990s (men) and then decreased thereafter. Age-period-cohort analysis showed that pancreatic cancer death risk was highest for the 1900 to 1910 birth cohort in men and the 1920 to 1930 birth cohort in women and there was a statistically significant increase in period effects since the late 1990s in both white men and white women (two-sided Wald test, P < .001).
CONCLUSIONS: In the United States, whites and blacks experienced opposite trends in pancreatic cancer death rates between 1970 and 2009 that are largely unexplainable by known risk factors. This study underscores the needs for urgent action to curb the increasing trends of pancreatic cancer in whites and for better understanding of the etiology of this disease.

Entities:  

Mesh:

Year:  2013        PMID: 24203988     DOI: 10.1093/jnci/djt292

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  59 in total

Review 1.  Noncoding RNAs and pancreatic cancer.

Authors:  Juan-Fei Peng; Yan-Yan Zhuang; Feng-Ting Huang; Shi-Neng Zhang
Journal:  World J Gastroenterol       Date:  2016-01-14       Impact factor: 5.742

2.  Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors.

Authors:  Aslamuzzaman Kazi; Shengyan Xiang; Hua Yang; Liwei Chen; Perry Kennedy; Muhammad Ayaz; Steven Fletcher; Christopher Cummings; Harshani R Lawrence; Francisca Beato; Ya'an Kang; Michael P Kim; Andrea Delitto; Patrick W Underwood; Jason B Fleming; Jose G Trevino; Andrew D Hamilton; Said M Sebti
Journal:  Clin Cancer Res       Date:  2019-06-21       Impact factor: 12.531

3.  Contribution of microRNAs in understanding the pancreatic tumor microenvironment involving cancer associated stellate and fibroblast cells.

Authors:  Shadan Ali; Raagini Suresh; Sanjeev Banerjee; Bin Bao; Zhihong Xu; Jeremy Wilson; Philip A Philip; Minoti Apte; Fazlul H Sarkar
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

4.  Optimal indication of neoadjuvant chemoradiotherapy for pancreatic cancer.

Authors:  Masayuki Sho; Takahiro Akahori; Toshihiro Tanaka; Shoichi Kinoshita; Minako Nagai; Satoshi Nishiwada; Tetsuro Tamamoto; Hideyuki Nishiofuku; Chiho Ohbayashi; Masatoshi Hasegawa; Kimihiko Kichikawa; Yoshiyuki Nakajima
Journal:  Langenbecks Arch Surg       Date:  2015-05-01       Impact factor: 3.445

Review 5.  Update on the role of nanoliposomal irinotecan in the treatment of metastatic pancreatic cancer.

Authors:  Fnu Asad Ur Rahman; Saeed Ali; Muhammad Wasif Saif
Journal:  Therap Adv Gastroenterol       Date:  2017-04-26       Impact factor: 4.409

6.  A web tool for age-period-cohort analysis of cancer incidence and mortality rates.

Authors:  Philip S Rosenberg; David P Check; William F Anderson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-08-21       Impact factor: 4.254

7.  Pancreatic cancer incidence trends: evidence from the Surveillance, Epidemiology and End Results (SEER) population-based data.

Authors:  Vanessa L Gordon-Dseagu; Susan S Devesa; Michael Goggins; Rachael Stolzenberg-Solomon
Journal:  Int J Epidemiol       Date:  2018-04-01       Impact factor: 7.196

8.  Postoperative prognosis of pancreatic cancer with para-aortic lymph node metastasis: a multicenter study on 822 patients.

Authors:  Masayuki Sho; Yoshiaki Murakami; Fuyuhiko Motoi; Sohei Satoi; Ippei Matsumoto; Manabu Kawai; Goro Honda; Kenichiro Uemura; Hiroaki Yanagimoto; Masanao Kurata; Takumi Fukumoto; Takahiro Akahori; Shoichi Kinoshita; Minako Nagai; Satoshi Nishiwada; Michiaki Unno; Hiroki Yamaue; Yoshiyuki Nakajima
Journal:  J Gastroenterol       Date:  2014-10-24       Impact factor: 7.527

9.  Genetic variants in the platelet-derived growth factor subunit B gene associated with pancreatic cancer risk.

Authors:  Bensong Duan; Jiangfeng Hu; Hongliang Liu; Yanru Wang; Hongyu Li; Shun Liu; Jichun Xie; Kouros Owzar; James Abbruzzese; Herbert Hurwitz; Hengjun Gao; Qingyi Wei
Journal:  Int J Cancer       Date:  2017-12-04       Impact factor: 7.396

10.  Disparities by Race, Age, and Sex in the Improvement of Survival for Major Cancers: Results From the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program in the United States, 1990 to 2010.

Authors:  Chenjie Zeng; Wanqing Wen; Alicia K Morgans; William Pao; Xiao-Ou Shu; Wei Zheng
Journal:  JAMA Oncol       Date:  2015-04       Impact factor: 31.777

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.